MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

Inclusion Criteria: * Participant had at least a 6-month history of migraine, with or without aura * Participant was male, or if female, must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions * Participant was judged to be in good health, apart from migraine Exclusion Criteria: * Participant was Pregnant or a nursing mother * Participant had a history or current evidence of drug or alcohol abuse * Participant had a history or clinical evidence of cardiovascular disease * Participant had a clinically significant Electrocardiography (ECG) abnormality * Participant had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening * Participant had received treatment with an investigational device or compound within 30 days of the study * Participant typically suffered from less then 1 or more than 8 attacks of migraine per month * Participant had difficulty in distinguishing his/her migraine attacks from tension or interval headaches * Participant was currently taking monoamine oxidase inhibitors, methysergide or lithium